CognoSpeak is a new AI tool that uses consultations and tests to generate memory questions that help with early dementia assessment.
Responses are examined for Alzheimer's and memory issues, producing a report for doctors and enhancing the effectiveness of care.
Speech patterns provide cognitive health insights, and AI developed at the University of Sheffield extracts indicators for quick evaluation.
By accelerating patient screening and specialist referrals and harmonising with international medical departments, AI integration streamlines primary care.
The success of a similar AI stroke diagnostic tool pushes the NHS in the UK and others to consider integration for faster care.
CognoSpeak expedites the diagnosis of dementia, allowing clinicians to spend less time on administrative tasks and begin treatment sooner.
The CognoSpeak trials match the pen-and-paper tests used in the UK and have a 90% accuracy rate in predicting Alzheimer's disease.
AI not only expedites diagnostics but also helps with drug discovery, which has the potential to have a seismic influence on the pharmaceutical and healthcare industries.
Due to its many applications and lucrative returns, experts predict that AI will have a significant impact on healthcare and drugs.